Abstract
Oxygen therapy is the first-line treatment of acute hypoxemic respiratory failure (AHRF). In patients where low-flow oxygen systems are not sufficient; high flow nasal cannula (HFNC), which can deliver 100% humidified and heated oxygen at flow rates up to the nostril up to 60 L/min, has been widely used. The aim of this study is to investigate the factors affecting the success of HFNC treatment in adult patients with AHRF. Between January 2017 and 2018, medical records of cases with AHRF supported by HFNC treatment in the intensive care unit were evaluated. Treatment success is defined as avoidance of intubation. HFNC was applied to 37 cases of AHRF. The median age of the cases was 61 (19-85) years. Most frequent indication for HFNC was immunosuppressive pneumonia with 18 (48,6%) cases. HFNC success was 51,4% with 19 cases. The mortality of those who failed HFNC was found to be significantly higher than the mortality of the successful ones (94% vs. 28,8%, respectively, p <0,001). PaO2, PaO2/FiO2 and lactate medians were statistically significantly different between the successful and unsuccessful groups [88 (50-160) vs 70,5 (50-132) p = 0,04; 174 (76-320) vs 102 (55-160) p = 0,02; 1. 5 (0. 7-5) vs 2. 3 (0. 6-6. 9) p = 0,02]. The SOFA score and the APACHE II score were found to be statistically significantly different between the successful and the unsuccessful groups (5,95 ± 3,04 versus 8,28 ± 2,74, p = 0,02; 17 ± 4,8 vs 24 ± 5,9 p <0,001 respectively). As a result; HFNC has a high mortality rate in unsuccessful cases. For this reason, knowing the factors contributing to the prediction of failed events may contribute to reducing mortality.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2296.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018